Astrazeneca Pharma India Ltd

Overview

AstraZeneca Pharma India Ltd (AstraZeneca), a subsidiary of AstraZeneca Plc, is a biopharmaceutical company. It discovers, develops, supplies and commercializes medicines. The company’s product portfolio include Forxiga, Imdur, Crestor, Tagrisso, Lynparza, Betaloc, Symbicort, budesonide, formoterol inhalation powder and Seloken. AstraZeneca offers products in the therapeutic areas including cardiovascular and metabolic diseases, respiratory, oncology,renal, inflammation, autoimmunity, infection, and gastrointestinal. The company operates in China, India, Singapore, Indonesia, Australia, Malaysia, the US, and the UK. AstraZeneca is headquartered in Bengaluru, Karnataka, India.
Key Stats
Address
Ni 12Th Floor, Manyata Empassy Business, Park Rachenahalli, Outer Ring Rd Kr Puram, Rachenahalli, BANGALORE, India
Headquarters

India

Contact

91 80 67748000

No of Employees

1,283

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

ASTRAZEN [NSE]

Revenue (2021)

$110 m

-2.3% (2021 vs 2020)
Net Income (2021)

$13 m

33.1% (2021 vs 2020)
Net Profit Margin

11 %

32.1% (2021 vs 2020)
Market Cap *

$1,086 m

EPS *

$0.5

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Astrazeneca Pharma India LtdCipla LtdAlembic Pharmaceuticals LtdGlaxoSmithKline Pharmaceuticals Ltd
Key Information
Headquarters India India India India
Headquarter City BANGALORE MUMBAI VADODARA MUMBAI
Headquarter State/Province - - - -
No. of Employees 1,283 21,565 12,160 4,283
Entity Type Public Public Public Public

Products & Services

AstraZeneca operates as a provider of biopharmaceutical products. The major products of the company include the following:

Products
  • Forxiga
  • Imdur
  • Betaloc
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • Brilinta
  • Xigduo XR
  • Zoladex
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In July, the company entered into a memorandum of understanding with Docon Technologies for digitizing…
2020 Contracts/Agreements In November, the company entered into a memorandum of understanding with the Research Society for…
2019 Contracts/Agreements In June, AstraZeneca Pharma signed a distribution agreement with Abbott Healthcare for Dapagliflozin.
2016 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2015 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2015 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
28 May 2021 AstraZeneca Pharma and Abbott Healthcare Terminate Distribution Agreement of Dapagliflozin Partnership Astrazeneca Pharma India Ltd; Abbott Healthcare Pvt Ltd
20 Jan 2017 Zydus Cadila Healthcare May Acquire 8 brands from Astrazeneca India Asset Transaction Cadila Healthcare Ltd Astrazeneca Pharma India Ltd
23 Mar 2016 Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin Partnership Sun Pharmaceutical Industries Ltd; Astrazeneca Pharma India Ltd
02 Jun 2015 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
29 May 2015 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
06 Mar 2012 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit